Lawyer Bio : Mark David Jenkins

Bar Associations: Tennessee Bar.

Admitted to the bar, 2005, Tennessee; 2008, District of Columbia; 2009, North Carolina.

Admitted to practice before the U.S. Patent and Trademark Office, 2006.

B.S., Chemistry, summa cum laude, 1998, University of Tennessee; MS, Chemistry, 2000, Vanderbilt University; J.D., cum laude, 2005, Franklin Pierce Law Center, Concord, New Hampshire.

Associate Attorney, 2005-2007, Summer Associate, 2004, Baker, Donelson, Bearman, Caldwell & Berkowitz, PC, Memphis, Tennessee, 2005-2007.

Analytical Chemist, Baxter Healthcare, Memphis, Tennessee, 2001-2002; Product Development Chemist, Buckeye Technologies Inc., Memphis, Tennessee, 2000-2001.

Co-Author, "The Knorr-Bremse Decision: A New Frontier in the Evolution of Willful Infringement," May 2005, (Runner Up Boston Patent Law Association Writing Competition);

"Bayer AG v. Housey Pharmaceuticals: An Important Decision for Drug Development," Germeshausen Center Newsletter, Spring 2004;

Co-Author, "Stent Wars: The Intellectual Property Battle Continues," Germeshausen Center Newsletter, Octob er 2 003;

Co-Author, "Structural Refinement of the 8,9-Dihydro-8-(N7-guanyl)-9-hydroxy-aflatoxin B1 Adduct in a 5'-CpA^FBG-3' Sequence" (2002) Chem. Res. Toxicol. 15, 638-647.

Speaker, "Prospects for a United States Approval Pathway for Biosimilar Biologics," American Society of Health System Pharmacists mid year clinical meeting, Las Vegas, Nevada, December 2007;

Speaker, "Intellectual Property in Business Transactions," Mississippi Bar Association IP Section CLE, Jackson, Mississippi, June 2006;